Abstract
Scleroderma renal crisis (SRC) is an uncommon complication of systemic sclerosis. Despite the advent of angiotensin-converting inhibitor therapy, SRC remains a life-threatening complication. Recent studies have contributed to a better understanding of SRC, but much remains unknown regarding its pathophysiology, risk factors, and optimal management. Genetic studies provide evidence that immune dysregulation might be a contributing factor, providing hope that further research in this direction might illuminate pathogenesis and provide novel predictors for this complication.
Original language | English (US) |
---|---|
Article number | 5 |
Pages (from-to) | 1-6 |
Number of pages | 6 |
Journal | Current rheumatology reports |
Volume | 18 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2016 |
Keywords
- Angiotensin-converting enzyme inhibitor (ACEI)
- Diffuse cutaneous disease (dcSSc)
- Immune dysregulation
- Malignant hypertension
- Renal biopsy
- Scleroderma renal crisis (SRC)
- Systemic sclerosis
- Thrombotic microangiopathy
ASJC Scopus subject areas
- Rheumatology